A Single-Arm, Open-Label Phase II Clinical Trial of SHR-1210 (camrelizumab) in Combination with Nimotuzumab in the Second-Line Treatment of Advanced Esophageal Squamous Cell Carcinoma.
JOURNAL OF CLINICAL ONCOLOGY（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined